Neurosoft Bioelectronics Raises $7.5M to Advance Brain-Computer Interface Platform

Neurosoft Bioelectronics Raises $7.5M to Advance Brain-Computer Interface Platform

Advertisement

The round was led by Skybound Venture Capital, with participation from IAG Capital Partners, Connecticut Innovations, PL Capital, and other investors.

Neurosoft Bioelectronics has raised $7.5 million in an oversubscribed seed funding round to advance its minimally invasive brain-computer interface (BCI) technology, bringing its total funding to more than $20 million.

The round was led by Skybound Venture Capital, with participation from IAG Capital Partners, Connecticut Innovations, PL Capital, and other investors.

Neurosoft Bioelectronics is developing a neural data platform based on minimally invasive, implantable brain-computer interface systems designed to record and interpret large-scale neural activity without penetrating brain tissue. The company operates between New York and Switzerland.

The system uses soft-material engineering and AI-driven analysis to collect neural signals and build what it describes as a “foundation model” of the human cortex. The model is trained on large-scale neural recordings captured through its implantable devices, drawing a parallel to how large language models are trained on text data.

The company is currently focused on neurological disorders, including tinnitus and epilepsy, using its BCI platform to restore function in affected patients. It also plans to expand the technology toward noninvasive human-machine communication applications in the future.

The newly raised capital will support human patient deployment and U.S. commercialization efforts.

Neurosoft Bioelectronics said its long-term goal is to develop scalable brain interfaces that could serve as a general communication layer between humans and machines.

The company recently partnered with neural engineering firm Science Corporation to access its ecosystem of neural recording tools, software, and manufacturing infrastructure to accelerate human trials and reduce early-stage development constraints.

Other players in the brain-computer interface space include companies such as Neuralink, INBRAIN Neuroelectronics, and Precision Neuroscience.

Stay tuned for more such updates on Digital Health News

Follow us

More Articles By This Author


Show All

Sign In / Sign up